Analysis of two-year treatment with omalizumab patients with severe asthma in real clinical practice

Objective: to evaluate the clinical efficacy and safety of long-term anti-IgE therapy patients with severe uncontrolled asthma.Materials and Methods: in Chelyabinsk city from November 2016 35 patients regularly receive omalizumab therapy - 9 men (26%) and 26 women (74%), the average age 44.5±14.1 years, the duration of asthma - 25.2±11.5 years. All patients had allergic pathology: allergic rhinitis - 100%, pollinosis - 79.4%, food allergy - 44.1%, atopic dermatitis - 26.5%. The level of total IgE in the blood is from 72 to 787 IU/ml, high sesitization to household (88.6%), epidermal (62.9%), pollen (74.3%) allergens was detected. All patients received basic therapy of ICS and LABA in high doses, 28 (82.35%) additionally took systemic corticosteroids, 19 (55.9%) anti-leukotriene preparations and 12 (34.3%) used tiotropium.For 24 months of anti-IgE-therapy there were no severe exacerbations of asthma, there were no hospitalizations, cancelled took systemic corticosteroids. All patients decreased the frequency of daytime (by 88.1%) and night (by 98.2%) symptoms, on 81.9% reduced the need to use SABA. Over 2 years of therapy the quality of life of patients improved significantly according to the AST test (5.6±0.91 vs 20.9±2.11, p<0.001) and the ACQ-7 (3.61±0.52 vs 1.22±0.66, p<0.001). 75.7% haven’t symotoms of allergic rhinitis. Respiratory function improved significantly: initially FEV1=60.19±2.9%, after 24 months trea...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Airway pharmacology and treatment Source Type: research